Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute
March 4, 2026 6:24 AM
IH Market News
Moderna (NASDAQ:MRNA) has reached a settlement worth up to $2.25 billion with Genevant Sciences, a subsidiary of Roivant Sciences (NASDAQ:ROIV), and Arbutus Biopharma (NASDAQ:ABUS), resolving a patent dispute tied to its COVID-19 vaccine.
The agreement brings to an end multiple legal cases in the United States and internationally that alleged Moderna used lipid nanoparticle (LNP) delivery technology developed by Genevant and Arbutus in its vaccine without authorization.
Analysts at William Blair described the settlement as a constructive outcome for Moderna, noting that the resolution removes a major legal uncertainty and provides the company with greater financial clarity as it approaches several late-stage oncology trial readouts expected in 2026.
Moderna stock price
Original: Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute
Market Data 
Markets 
AI
